Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug/Diagnostic R&D Guidance Will Accommodate Biomarker Data Diversity

This article was originally published in The Gray Sheet

Executive Summary

A retrospective study approach to drug and diagnostic co-development may be appropriate to verify a test's clinical utility in certain cases, FDA notes in a draft concept paper

You may also be interested in...

In Long-Awaited Guidance, FDA Lays Out Approval Path For Drugs And Companion Dxs

Draft document addresses how FDA expects drugs and devices to be developed contemporaneously and how those products will be reviewed simultaneously by the relevant regulatory centers at FDA with collaboration across divisions.

FDA's Seyfert-Margolis On Companion Diagnostics Guidance

Industry is anxiously awaiting guidance from FDA on the development of companion diagnostics for drugs that will inform efforts to move towards personalized medicine.

FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance

FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts